Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

From Rags to Riches: Bladder Cancer Research Rife With New Approaches

September 27th 2016

For decades, research into bladder cancer treatments was stagnant, but now science has moved into a period rife with new approaches — immunotherapy chief among them.

Creating a Diversion: Life After Cystectomy for Bladder Cancer

September 22nd 2016

After the bladder is surgically removed and the urinary system diverted, most can return to their usual activities.

3 Questions: The Impact of Tecentriq to Treat Patients With Advanced Bladder Cancer

September 19th 2016

Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

Setback for Novel Agent to Treat Subset of Patients With Bladder Cancer

September 19th 2016

The FDA voted against approving Qapzola for treatment of some patients with bladder cancer.

BCAN Focused on Building a High-Energy Community for Bladder Cancer

September 16th 2016

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

6 Questions With a Physician: Tecentriq, Immunotherapies for Bladder Cancer

August 22nd 2016

After a long lapse in advancements for bladder cancer, the approval of Tecentriq is changing the field.

Gaining a Better Understanding of Immunotherapy in Bladder Cancer

August 17th 2016

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

Expert Discusses Changing Field of Immunotherapy to Treat Genitourinary Cancers

August 13th 2016

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

Improving Care for Patients With Muscle-Invasive Bladder Cancer

July 20th 2016

CURE spoke with Stanley Yap about how physicians can improve care for patients with muscle-invasive bladder cancer.

Early Immunotherapy Data: 8 Questions With a Bladder Cancer Expert

July 19th 2016

The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.

Opdivo Making Strides in Advanced Bladder Cancer

July 7th 2016

“Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo,” said Jean Viallet.

Large Analysis Finds Men Live Longer With Bladder Cancer Than Women

June 23rd 2016

A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.

Early Trial Data Provide Reason for Hope in Bladder Cancer

June 15th 2016

A recent phase 1 study shows promise for the treatment of bladder cancer.

Tecentriq Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

FDA Approves Tecentriq for Metastatic Bladder Cancer

May 19th 2016

Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.

Arsenic in New England Well Water Suspected Root of 50-Year Bladder Cancer Rise

May 18th 2016

Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.

Expert Discusses Development of Atezolizumab for Bladder Cancer

May 13th 2016

The approval of atezolizumab will change the treatment paradigm of bladder cancer overnight, says Robert Dreicer.

Predicting Response in Kidney and Bladder Cancer Remains in a State of Flux

May 9th 2016

Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.

Recent Study Findings Represent "Watershed Moment" in Metastatic Bladder Cancer

April 21st 2016

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.

Durvalumab Continues to Progress in Treatment of Advanced Bladder Cancer

April 1st 2016

The FDA's breakthrough designation is meant to expedite the development of therapies that offer substantial benefits over existing options.

Bladder Cancer Advocacy Network Shines Spotlight on Common, But Unknown Killer

March 29th 2016

First Study of Immunotherapy/Chemo Combo Fails to Show Significant Benefit in Urothelial Cancer

January 26th 2016

"Response rate and survival were similar to historical controls, and the primary endpoint was not met," said lead investigator Matthew Galsky.

Immunotherapy Research Continues in Bladder Cancer

November 18th 2015

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

Fall Patient Insight Webinars from the Bladder Cancer Advocacy Network

October 20th 2015

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

Genomic Profiling Study Brings Personalized Medicine to Metastatic Bladder Cancer Patients

September 24th 2015

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.

Patient Blog: Sharing My Story of Bladder Cancer to Help Others

July 25th 2015

Rick Bulifant shares his bladder cancer story.

CURE Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer

May 27th 2015

CURE Magazine and the Bladder Cancer Advocacy Network (BCAN), whose mission is to advance research, provide information and support, and raise awareness of bladder cancer, have joined forces to battle the fifth most common type of cancer, which begins when the cells in the bladder's lining start to grow out of control.

Keytruda Shows Activity in Urothelial Cancer

May 20th 2015

Data from an ongoing trial showed that one fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor Keytruda.

Dr. Bishoy Faltas on the Future of Bladder Cancer Therapy

April 18th 2015

Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.

Combining Radiation and Chemotherapy May Improve Outcomes

March 13th 2013

In the right cancer, radiation and chemotherapy can make a powerful duo.